Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C14H19N2O2.Cl |
| Molecular Weight | 282.766 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].C[N+](C)(C)[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O
InChI
InChIKey=NZXZRRFENSICAK-ZOWNYOTGSA-N
InChI=1S/C14H18N2O2.ClH/c1-16(2,3)13(14(17)18)8-10-9-15-12-7-5-4-6-11(10)12;/h4-7,9,13,15H,8H2,1-3H3;1H/t13-;/m0./s1
| Molecular Formula | C14H18N2O2 |
| Molecular Weight | 246.3049 |
| Charge | 0 |
| Count |
|
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Hypaphorine is the alkaloid isolated from the seeds of Brazilian medicinal plant Erythrina spp. This compound was investigated for sleep-promoting effects in mice, and the results showed that it significantly increased non-rapid eye movement (NREM) sleep time during the first hour after its administration. Hypaphorine prevented the differentiation of 3T3-L1 preadipocytes into adipocytes by down-regulating hormone-stimulated protein expression of peroxisome proliferator activated receptor γ (PPARγ) and CCAAT/enhancer binding protein (C/EBPα), and their downstream targets, sterol regulatory element binding protein 1 c (SREBP1c) and fatty acid synthase (FAS). Hypaphorine may exert anti-inflammatory actions through the regulation of TLR4 and PPAR-γ dependent on PI3K/Akt/mTOR signal pathways. It is considered as a therapeutic agent that can potentially relieve or ameliorate endothelial inflammation-associated diseases. Hypaphorine was also a key component of Vaccaria segetalis. Vaccaria hypaphorine might be considered as a potential therapeutic agent for treating osteoclast-based bone loss.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0030316 Sources: https://www.ncbi.nlm.nih.gov/pubmed/29136954 |
|||
Target ID: WP1403 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28683454 |
|||
Target ID: map04150 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28420166 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Vaccaria hypaphorine impairs RANKL-induced osteoclastogenesis by inhibition of ERK, p38, JNK and NF-κB pathway and prevents inflammatory bone loss in mice. | 2018-01 |
|
| Hypaphorine, an Indole Alkaloid Isolated from Caragana korshinskii Kom., Inhibites 3T3-L1 Adipocyte Differentiation and Improves Insulin Sensitivity in Vitro. | 2017-07 |
|
| Hypaphorine Attenuates Lipopolysaccharide-Induced Endothelial Inflammation via Regulation of TLR4 and PPAR-γ Dependent on PI3K/Akt/mTOR Signal Pathway. | 2017-04-17 |
|
| Vaccaria hypaphorine alleviates lipopolysaccharide-induced inflammation via inactivation of NFκB and ERK pathways in Raw 264.7 cells. | 2017-02-20 |
|
| Interactions of TLR4 and PPARγ, Dependent on AMPK Signalling Pathway Contribute to Anti-Inflammatory Effects of Vaccariae Hypaphorine in Endothelial Cells. | 2017 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29136954
Mice: 10 and 30 mg/kg (1 d before LPS injection and then every other 7 d.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29136954
12.5 uM, 25 uM or 50 uM vaccaria hypaphorine markedly disturbed F-actin ring structure, indicating that vaccaria hypaphorine could inhibit bone-resorbing activity of osteoclasts.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:06:19 GMT 2025
by
admin
on
Mon Mar 31 22:06:19 GMT 2025
|
| Record UNII |
6444YS784R
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
91617793
Created by
admin on Mon Mar 31 22:06:19 GMT 2025 , Edited by admin on Mon Mar 31 22:06:19 GMT 2025
|
PRIMARY | |||
|
20671-76-5
Created by
admin on Mon Mar 31 22:06:19 GMT 2025 , Edited by admin on Mon Mar 31 22:06:19 GMT 2025
|
PRIMARY | |||
|
m6170
Created by
admin on Mon Mar 31 22:06:19 GMT 2025 , Edited by admin on Mon Mar 31 22:06:19 GMT 2025
|
PRIMARY | Merck Index | ||
|
6444YS784R
Created by
admin on Mon Mar 31 22:06:19 GMT 2025 , Edited by admin on Mon Mar 31 22:06:19 GMT 2025
|
PRIMARY |